'The more overhype, the harder you fall': Schrödinger CEO warns on AI craze

Andrew Dunn

Senior Biopharma Correspondent

When sell-side analyst Evan Seigerman was preparing to start covering the startup Schrödinger this spring, he rang up the $3.5 billion biotech’s chief financial officer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'The more overhype, the harder you fall': Schrödinger CEO warns on AI craze

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA says Ozempic, Wegovy shortage is over

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Merck KGaA tees up changes to leadership team; Ex-CVS Health CEO joins Thermo Fisher’s board

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

'The more over­hype, the hard­er you fal­l': Schrödinger CEO warns on AI craze

Senior Biopharma Correspondent

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

'The more overhype, the harder you fall': Schrödinger CEO warns on AI craze